Naked mole rats defy the biological law of aging

Link: https://www.science.org/content/article/naked-mole-rats-defy-biological-law-aging

Excerpt:

The first study to analyze the life histories of thousands of naked mole rats has found that their risk of death doesn’t go up as they grow older, as it does for every other known mammalian species. Although some scientists caution against any sweeping conclusions, many say the new data are important and striking.

“This is remarkably low mortality,” says Caleb Finch, a biogerontologist at the University of Southern California in Los Angeles who was not involved in the new study. “At advanced ages, their mortality rate remains lower than any other mammal that has been documented.”

Scientists have long noted that naked mole rats—burrowing rodents with wrinkled, pink skin and large protruding teeth that live in large, subterranean colonies—show few signs of aging and far surpass the life span expected of a rodent this size. Mice in captivity live at most 4 years; based on their size, naked mole rats would not be expected to live past 6 years. Instead, some live beyond 30 years, and even at that age breeding females stay fertile.

Author(s): KAI KUPFERSCHMIDT

Publication Date: 26 JAN 2018

Publication Site: Science

The economic value of targeting aging

Link: https://www.nature.com/articles/s43587-021-00080-0?fbclid=IwAR30GYDrmx1ck_1CkFvkoJUR4EttL4OxkNOgD9ZYft_jvqYa-inOhhthZao

Graphic:

Excerpt:

Developments in life expectancy and the growing emphasis on biological and ‘healthy’ aging raise a number of important questions for health scientists and economists alike. Is it preferable to make lives healthier by compressing morbidity, or longer by extending life? What are the gains from targeting aging itself compared to efforts to eradicate specific diseases? Here we analyze existing data to evaluate the economic value of increases in life expectancy, improvements in health and treatments that target aging. We show that a compression of morbidity that improves health is more valuable than further increases in life expectancy, and that targeting aging offers potentially larger economic gains than eradicating individual diseases. We show that a slowdown in aging that increases life expectancy by 1 year is worth US$38 trillion, and by 10 years, US$367 trillion. Ultimately, the more progress that is made in improving how we age, the greater the value of further improvements.

Author(s): Andrew J. Scott, Martin Ellison, David A. Sinclair

Publication Date: 5 July 2021

Publication Site: Nature Aging